- |||||||||| fluticasone propionate / Generic mfg.
Phase classification, Enrollment change: Seal, Stopping Eczema and Allergy Study (clinicaltrials.gov) - May 10, 2024
P2, N=312, Recruiting,
Phase classification: P3 --> P2 | N=750 --> 312
- |||||||||| fluticasone propionate / Generic mfg.
Phase classification, Trial primary completion date: Seal, Stopping Eczema and Allergy Study (clinicaltrials.gov) - May 7, 2024
P3, N=750, Recruiting,
Phase classification: P3 --> P2 | N=750 --> 312 Phase classification: P2 --> P3 | Trial primary completion date: Jul 2026 --> May 2027
- |||||||||| budesonide / Generic mfg.
Journal: Recent insights on the use of topical steroids in eosinophilic esophagitis. (Pubmed Central) - Aug 13, 2021
Current evidence suggests that maintenance therapy with long-term topical steroids decreases the risk of relapse and progression to fibrostenotic disease. While uncertainty over the dose and duration of maintenance topical steroids and their potential side effects exists, long-term maintenance therapy with topical steroids appears to be the way forward to improve long-term outcomes in patients with EoE.
- |||||||||| fluticasone propionate / Generic mfg.
Enrollment open: Seal, Stopping Eczema and Allergy Study (clinicaltrials.gov) - Jul 8, 2021
P2, N=875, Recruiting,
While uncertainty over the dose and duration of maintenance topical steroids and their potential side effects exists, long-term maintenance therapy with topical steroids appears to be the way forward to improve long-term outcomes in patients with EoE. Not yet recruiting --> Recruiting
- |||||||||| fluticasone propionate / Generic mfg.
Phase classification: Seal, Stopping Eczema and Allergy Study (clinicaltrials.gov) - May 21, 2021
P2, N=875, Not yet recruiting,
Not yet recruiting --> Recruiting Phase classification: P1/2 --> P2
- |||||||||| fluticasone propionate / Generic mfg.
Trial completion date, Trial primary completion date: Seal, Stopping Eczema and Allergy Study (clinicaltrials.gov) - Jul 16, 2020
P1/2, N=750, Not yet recruiting,
No abstract available Trial completion date: Dec 2023 --> Jul 2027 | Trial primary completion date: Dec 2020 --> Jul 2026
- |||||||||| fluticasone propionate / Generic mfg.
Trial completion date, Trial initiation date, Trial primary completion date: Seal, Stopping Eczema and Allergy Study (clinicaltrials.gov) - Sep 22, 2019
P1/2, N=750, Not yet recruiting,
Trial completion date: Dec 2023 --> Jul 2027 | Trial primary completion date: Dec 2020 --> Jul 2026 Trial completion date: Dec 2020 --> Dec 2023 | Initiation date: Feb 2019 --> Jun 2020 | Trial primary completion date: Apr 2020 --> Dec 2020
- |||||||||| fluticasone propionate / Generic mfg.
New P4 trial: Dermatitis Study (EUDRACT) - Oct 19, 2017
P4, N=123, ,
- |||||||||| fluticasone propionate / Generic mfg.
Enrollment change, Trial withdrawal, Combination therapy: Fractional Laser in Combination With UVB Therapy in Vitiligo Patients (clinicaltrials.gov) - Apr 18, 2016
P=N/A, N=0, Withdrawn,
Trial completion date: Dec 2020 --> Dec 2023 | Initiation date: Feb 2019 --> Jun 2020 | Trial primary completion date: Apr 2020 --> Dec 2020 N=20 --> 0 | Recruiting --> Withdrawn
- |||||||||| fluticasone propionate / Generic mfg.
Enrollment open, Trial initiation date, Combination therapy: Fractional Laser in Combination With UVB Therapy in Vitiligo Patients (clinicaltrials.gov) - May 29, 2015
P=N/A, N=20, Recruiting,
N=20 --> 0 | Recruiting --> Withdrawn Not yet recruiting --> Recruiting | Initiation date: Jan 2015 --> May 2015
- |||||||||| pimecrolimus topical / Generic mfg., fluticasone propionate / Generic mfg.
Trial completion, Combination therapy: Combination Therapy for Atopic Dermatitis (clinicaltrials.gov) - Feb 22, 2014
P4, N=90, Completed,
Not yet recruiting --> Recruiting | Initiation date: Jan 2015 --> May 2015 No longer recruiting --> Completed
|
